Agenus (NASDAQ:AGEN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Agenus Inc. (NASDAQ:AGEN)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.08 and traded as high as $4.84. Agenus shares last traded at $4.80, with a volume of 750,338 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. B. Riley restated a “buy” rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright upgraded shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, June 4th. Wall Street Zen upgraded shares of Agenus from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. Finally, Robert W. Baird raised their price target on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, June 4th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Agenus has a consensus rating of “Hold” and a consensus price target of $14.00.

Agenus Trading Up 0.4%

The stock has a market cap of $131.62 million, a P/E ratio of -0.55 and a beta of 1.43. The firm’s fifty day moving average is $3.68 and its 200 day moving average is $3.08.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. Research analysts forecast that Agenus Inc. will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. B. Riley Financial Inc. acquired a new stake in Agenus in the 4th quarter worth $2,074,000. Siren L.L.C. acquired a new stake in Agenus in the 1st quarter worth $752,000. AQR Capital Management LLC grew its position in Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the last quarter. Gilead Sciences Inc. acquired a new stake in shares of Agenus during the 4th quarter valued at about $635,000. Finally, Strs Ohio acquired a new stake in shares of Agenus during the 1st quarter valued at about $214,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.